Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer
Background. Small-molecule tyrosine inhibitor anlotinib which developed in China has been approved as a third-line treatment for patients with small-cell lung cancer (SCLC). Our previous clinical study found that anlotinib combined with S-1 has better short-term ORR than the single-agent anlotinib o...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2022/4484211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554802877300736 |
|---|---|
| author | Xinhang Xia Wenhu Pi Yanli Lan Xiaomai Wu Dongqing Lv Yinnan Meng Haihua Yang Wei Wang |
| author_facet | Xinhang Xia Wenhu Pi Yanli Lan Xiaomai Wu Dongqing Lv Yinnan Meng Haihua Yang Wei Wang |
| author_sort | Xinhang Xia |
| collection | DOAJ |
| description | Background. Small-molecule tyrosine inhibitor anlotinib which developed in China has been approved as a third-line treatment for patients with small-cell lung cancer (SCLC). Our previous clinical study found that anlotinib combined with S-1 has better short-term ORR than the single-agent anlotinib of SCLC and other small-molecule vascular targeted drug therapies in the treatment of SCLC. However, the molecular mechanism of those effect remains unclear. Methods. SCLC cell line H446 was treated with either anlotinib, 5-FU alone, or combination. The cellular effects including cell viability, cell apoptosis, cell cycle, cell migration, and invasion were explored to evaluate the cell proliferation level. Western blot was performed to determine the protein levels of the combined action of the two drugs. The xenograft mouse model was established by injection of H446 cells into mouse, and the animals were randomized and assigned for the drug treatments. Body weights and tumor sizes were recorded. WB was conducted using tumor tissues. All data were collected and statistically analyzed using t-test to reveal the underlying molecular mechanism. Results. When anlotinib was combined with 5-FU, the IC50 value of cells was significantly reduced. And apoptosis, cell cycle arrest, and cell motility rates were stronger when anlotinib combined with 5-FU than in the anlotinib or 5-FU alone. In H446 cell-derived xenograft mouse model, tumor volumes were significantly decreased in Anlo/5-FU combination group than anlotinib or 5-FU alone group. Western blot showed the decreasing expression of p-Src/p-AKT in the Anlo/5-FU group. Conclusion. Our data revealed that the treatment of combination of antitumor angiogenesis agent anlotinib with chemotherapy drug 5-FU may have synergistic cytotoxicity to SCLC in vitro and in vivo. This treatment modality reduced cell proliferation and migration via Src/AKT pathway. This new strategy may be a promising treatment for SCLC but needs to be confirmed in future clinical trials. |
| format | Article |
| id | doaj-art-1410b23192b64c9ca0c797dd9770672b |
| institution | Kabale University |
| issn | 2210-7185 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-1410b23192b64c9ca0c797dd9770672b2025-02-03T05:50:30ZengWileyAnalytical Cellular Pathology2210-71852022-01-01202210.1155/2022/4484211Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung CancerXinhang Xia0Wenhu Pi1Yanli Lan2Xiaomai Wu3Dongqing Lv4Yinnan Meng5Haihua Yang6Wei Wang7Key Laboratory of Radiation Oncology of TaizhouKey Laboratory of Radiation Oncology of TaizhouKey Laboratory of Radiation Oncology of TaizhouDepartment of Pulmonary MedicineDepartment of Pulmonary MedicineKey Laboratory of Radiation Oncology of TaizhouKey Laboratory of Radiation Oncology of TaizhouKey Laboratory of Radiation Oncology of TaizhouBackground. Small-molecule tyrosine inhibitor anlotinib which developed in China has been approved as a third-line treatment for patients with small-cell lung cancer (SCLC). Our previous clinical study found that anlotinib combined with S-1 has better short-term ORR than the single-agent anlotinib of SCLC and other small-molecule vascular targeted drug therapies in the treatment of SCLC. However, the molecular mechanism of those effect remains unclear. Methods. SCLC cell line H446 was treated with either anlotinib, 5-FU alone, or combination. The cellular effects including cell viability, cell apoptosis, cell cycle, cell migration, and invasion were explored to evaluate the cell proliferation level. Western blot was performed to determine the protein levels of the combined action of the two drugs. The xenograft mouse model was established by injection of H446 cells into mouse, and the animals were randomized and assigned for the drug treatments. Body weights and tumor sizes were recorded. WB was conducted using tumor tissues. All data were collected and statistically analyzed using t-test to reveal the underlying molecular mechanism. Results. When anlotinib was combined with 5-FU, the IC50 value of cells was significantly reduced. And apoptosis, cell cycle arrest, and cell motility rates were stronger when anlotinib combined with 5-FU than in the anlotinib or 5-FU alone. In H446 cell-derived xenograft mouse model, tumor volumes were significantly decreased in Anlo/5-FU combination group than anlotinib or 5-FU alone group. Western blot showed the decreasing expression of p-Src/p-AKT in the Anlo/5-FU group. Conclusion. Our data revealed that the treatment of combination of antitumor angiogenesis agent anlotinib with chemotherapy drug 5-FU may have synergistic cytotoxicity to SCLC in vitro and in vivo. This treatment modality reduced cell proliferation and migration via Src/AKT pathway. This new strategy may be a promising treatment for SCLC but needs to be confirmed in future clinical trials.http://dx.doi.org/10.1155/2022/4484211 |
| spellingShingle | Xinhang Xia Wenhu Pi Yanli Lan Xiaomai Wu Dongqing Lv Yinnan Meng Haihua Yang Wei Wang Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer Analytical Cellular Pathology |
| title | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer |
| title_full | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer |
| title_fullStr | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer |
| title_full_unstemmed | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer |
| title_short | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer |
| title_sort | synergistic antitumor effects of anlotinib combined with oral 5 fluorouracil s 1 via inhibiting src akt signaling pathway in small cell lung cancer |
| url | http://dx.doi.org/10.1155/2022/4484211 |
| work_keys_str_mv | AT xinhangxia synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT wenhupi synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT yanlilan synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT xiaomaiwu synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT dongqinglv synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT yinnanmeng synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT haihuayang synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer AT weiwang synergisticantitumoreffectsofanlotinibcombinedwithoral5fluorouracils1viainhibitingsrcaktsignalingpathwayinsmallcelllungcancer |